HSP90AA1 and acquired epidermolysis bullosa: Our results are consistent with other animal studies in which HSP90 inhibition suppressed inflammatory pathways and improved the clinical course in inflammatory models (rheumatoid arthritis, systemic lupus erythematous, epidermolysis bullosa acquisita and psoriasis) (16–21).